SEC Comment Letter 0000000000-24-012892 to Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc.
Date: Nov. 20, 2024 · CIK: 0001937993 · Accession: 0000000000-24-012892
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283226
Letter
November 20, 2024 Quang Pham Chief Executive Officer Cadrenal Therapeutics, Inc. 822 A1A North, Suite 306 Ponte Vedra, FL 32082 Re:Cadrenal Therapeutics, Inc. Registration Statement on Form S-3 Filed November 14, 2024 File No. 333-283226 Dear Quang Pham: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Leslie Marlow, Esq.
Show Raw Text
November 20, 2024
Quang Pham
Chief Executive Officer
Cadrenal Therapeutics, Inc.
822 A1A North, Suite 306
Ponte Vedra, FL 32082
Re:Cadrenal Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 14, 2024
File No. 333-283226
Dear Quang Pham:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Leslie Marlow, Esq.